AndhraNews.net
Home » Features » Health » Kidney Cancer

Kidney Cancer


About Kidney Cancer

Researchers from Fox Chase Cancer Centre have shown that robot assisted kidney cancer surgery is more beneficial for patients compared to open surgery.

Kidney Cancer in News

Curb Energy Consumption
(Family Features) Water heaters are energy intensive appliances. In fact, they are the second largest energy user in the home, and as they age, they become less efficient, requiring even more energy.

Horizon Pharma plc and Fox Chase Cancer Center Temple Health Initiate Phase 1 Study to Evaluate ACTIMMUNE(R) (interferon gamma-1b) in Combination With Nivolumab in Patients With Advanced Solid Tumors

Phoenix Integrated Store Consultants Teams Up With the Make-A-Wish Foundation of Georgia(R)
Phoenix Integrated Store Consultants is proud to announce their partnership with the Make-A-Wish Foundation of Georgia® for the second year in a row for the company's annual Wings for Wishes Competition. This year the event will be held at the Wing Factory, owned by Corporate Sponsor, Kevin Parker, on Cumberland Boulevard in Atlanta

PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board
BONITA, CA--(Marketwired - July 21, 2015) - In the world of pharmaceuticals, the approval of a new drug is largely a matter of its relative performance rather than an absolute performance. That is, the therapy in question doesn't just have to work -- it has to work as good, or better, than the treatments currently approved for a particular disease.

Swinerton Raises $28,000 in Support of Make-A-Wish Northeastern California and Northern Nevada
Swinerton Builders Sacramento recently rallied together with local subcontractors and The Swinerton Foundation -- the company's nonprofit arm -- to raise $28,000 in support of Make-A-Wish® Northeastern California and Northern Nevada. Thanks to the tremendous efforts of Swinerton team members, the contributions will help grant the aspirations of local wish children and families

OCTANe Elects David Perry as New Chairman of the Board
OCTANe, the Orange County startup accelerator dedicated to enabling innovative technology companies and creating jobs in Orange County by connecting people and ideas with resources and capital, today announced the appointment of David Perry as non-executive chairman of the board.

Rosetta Genomics to Host Business Update Conference Call on September 18, 2014
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that following the close of the U.S. stock market on Wednesday, September 17, 2014, the Company will file financial results for the six months ended June 30, 2014 on Form 6-K with the U.S. Securities and Exchange Commission ("SEC")

Rosetta Genomics and Moffitt Cancer Center Enter Into Strategic Alliance to Develop microRNA-Based Cancer Diagnostics
Rosetta Genomics Ltd. (NASDAQ: ROSG) announces that the company has entered into a strategic alliance with Moffitt Cancer Center to discover, develop and commercialize a variety of microRNA-based cancer diagnostics.

Rosetta Genomics Reports Financial Results for the First Half of 2014
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today reported financial results for the six months ended June 30, 2014.

Rosetta Genomics Initiates Post-Marketing Registry Study of Its Cancer Origin Test
Rosetta Genomics Ltd

Rosetta Genomics Announces Next-Generation Sequencing Research Collaboration With Weizmann Institute of Science's Nancy and Stephen Grand Israel National Center for Personalized Medicine
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has entered into a collaborative research and license agreement with Yeda Research and Development Co. Ltd., the commercial arm of the Weizmann Institute of Science

Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test
PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - July 22, 2014) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announced that the New York State Department of Health ("NYSDOH") has given the Company final approval for its Rosetta Kidney Cancer Test™ for testing on patient samples from the State

Nuvilex Heads to the Clinic With an Opportunity to Treat a Wider Range of Cancers
Nuvilex, Inc. (OTCQB: NVLX) and its shareholders should soon experience an event that, to date, has not been enjoyed by the Maryland biotech firm

UPDATE: Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of microRNA-Based Cancer Diagnostic
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces that the Company has entered into an agreement with Moffitt Cancer Center to advance the development and commercialization of Rosetta's thyroid neoplasia assay.

Two Is Better Than One: New Procedure Pioneered at Henry Ford Hospital Saves Your Kidney After Cancer
DETROIT, MI--(Marketwired - May 14, 2014) - More than 30,000 kidney tumors are diagnosed annually in the United States.

Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay
Rosetta Genomics Ltd

Rosetta Genomics Reports 2013 Financial Results
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today reported financial results for the year ended December 31, 2013.

Rosetta Genomics Enters Collaboration With Clalit Health Services' Rabin Medical Center for microRNA-Based Assay for Chronic Allograft Dysfunction Following Kidney Transplantation
Rosetta Genomics Ltd

Rosetta Genomics' Cancer Origin Test Highlighted at Landmark CUP Foundation Seminar 2014
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, reports that the Company is sponsoring and participating in the CUP Foundation seminar 2014 taking place from March 21-22 in London, England

Rosetta Genomics Provides Product Pipeline Update
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces details regarding the Company's plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics.

Rosetta Genomics Announces Publication of Data Correlating miR-150 to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces data from a study of the Company's microRNA technology was published online in the American Journal of Cardiology in an article entitled, "Relation of Reduced Expression of MiR-150 in Platelets to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure

Rosetta Genomics to Receive Important U.S. Patent for Oncology Therapeutic
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming Mp53-negative cancer patients. The allowed claims for U.S. Patent Application No

Rosetta Genomics Executes Agreement With MultiPlan
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed an agreement with Mulitiplan, Inc. (Multiplan) for Rosetta's healthcare services including the Rosetta Cancer Origin Test™.

Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the appointment of Kevin Watson to the newly established role of Director, Reimbursement-Managed Care. Mr

Chicago Dentist Says Routine Dental Visits Can Help Prevent Oral Infection and Even Life-Threatening Disease
Dr. Sheldon Seidman, a cosmetic dentist in Chicago, says when patients begin to notice problems in the mouth, this usually means an oral infection may already exist and could have progressed to other parts of the body, posing even greater health risks. Dr

Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct

Rosetta Genomics Granted U.S. Patent Allowance for the Use of microRNAs to Treat Liver Cancer
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) related to U.S. Patent Application No. 13/481,105 titled "Targeting microRNAs for the Treatment of Liver Cancer."

Medical Cannabis Financial Group, Inc. Announces Merger Transaction With Refill Energy, Inc.
Refill Energy, Inc. (PINKSHEETS: REFG), a Nevada Corporation (the "Company") announces the merger between Refill Energy, Inc. and Medical Cannabis Financial Group. Refill Energy, Inc. completed a reorganization with Medical Cannabis Financial Group, Inc., which is a software solutions company focused on solutions for the Medical Marijuana industry

NewLink Genetics Launches Phase 1 Clinical Trial of Its HyperAcute(TM) Renal Immunotherapy in Patients With Metastatic Renal Cell Cancer
NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it had launched a first in human Phase 1 clinical trial of HyperAcute Renal immunotherapy in patients with metastatic renal cell cancer

Rosetta Collaborative Study Profiling microRNAs Published in Clinical & Translational Oncology
Rosetta Genomics Ltd

Rosetta Genomics Announces New York State Approval for the Rosetta Kidney Cancer Test(TM)
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announced that the New York State Department of Health ("NYSDOH") has given the Company conditional approval for the Rosetta Kidney Cancer Test™ for testing on patient samples from the State. New York is the only U.S

Rosetta Genomics Issues Letter to Shareholders
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the posting of the following Letter to Shareholders to the Investors section of the Company's website at www.rosettagenomics.com.

Rosetta Genomics to Participate in the LD Micro Conference
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in the LD Micro Conference being held December 3-5, 2013 at the Luxe Sunset Bel Air Hotel in Los Angeles.

Rosetta Genomics Expands microRNA Cancer Testing Services Agreement With GeneKor to Include Turkey and Romania
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the expansion of its distribution agreement with GeneKor Medical S

Rosetta Genomics Reports First Payment From the UK's National Health Service for the Rosetta Cancer Origin Test(TM)
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the National Health Service (NHS) of the United Kingdom (UK), the world's largest publicly-funded health service, has made its first payment to the Company for use of the Rosetta Cancer Origin Test™ on a British citizen

Rosetta Genomics Announces Sponsored Research Agreement With Ramot at Tel Aviv University
Rosetta Genomics Ltd

Rosetta Genomics' Announces Poster Presentation at the American Society of Human Genetics Annual Meeting 2013
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company's Cancer Origin Test™ will be highlighted in a poster presentation at the upcoming American Society of Human Genetics Annual Meeting 2013 (ASHG 2013) taking place October 22-26 at the Boston Convention and Exhibition Center in Boston, Mass.

Rosetta Genomics' Cancer Origin Test Incorporated Into Altos Solutions' OncoEMR(R) Software Electronic Medical Record
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Rosetta Cancer Origin Test™ will be incorporated into Altos Solutions, Inc.'s (Altos) Electronic Medical Records (EMR) system, OncoEMR®.

Rosetta Genomics to Participate at the Aegis Capital 2013 Healthcare Conference
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate at the Aegis Capital 2013 Healthcare Conference being held from September 25-28, 2013 at The Encore at Wynn Las Vegas.

Rosetta Genomics' Cancer Origin Test Highlighted on The Dr. Steve Show
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Rosetta Cancer Origin Test™ will be featured in an upcoming episode on The Dr. Steve Show, a nationally syndicated 30-minute health, well-being and lifestyle program. The segment is expected to air the first weekend in October 2013 in the following markets:

Rosetta Genomics Reports Financial Results for the First Six Months of 2013
Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reports financial results for the six months ended June 30, 2013.

Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed credentialing agreements with FedMed, Inc. (FedMed) and Fortified Provider Network Inc. (FPN) for Rosetta's Cancer Origin Test™.

Rosetta Genomics to Host Business Update Conference Call on September 10, 2013
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that following the close of the U.S. stock market on Monday, September 9, 2013, the Company will file its financial results for the six-month period ended June 30, 2013 on Form 6-K with the U.S. Securities and Exchange Commission ("SEC")

Cellceutix Reports In Vivo Tumor Shrinkage in Renal Cancer
Cellceutix Corporation (OTCBB: CTIX) (the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, announces today that the Company has received results from in vivo studies conducted at Beth Israel Deaconess Medical Center ("BIDMC")

Onyx Pharmaceuticals Reports Third Quarter 2012 Financial Results

PropThink: Biogen Idec's BG-12 PDUFA Delay is a Buying Opportunity
By Ivan Deryugin

PropThink: Biogen Idec's BG-12 PDUFA Delay is a Buying Opportunity
By Ivan DeryuginThe biotechnology sector can be broken up, at its simplest, into two distinct groups: the Big 4, and every other company. The Big 4 are Amgen (NASDAQ:AMGN), Celgene (NASDAQ:CELG), Gilead Sciences (NASDAQ:GILD), and Biogen Idec (NASDAQ:BIIB). Many investors view the Big 4 as stable investments, with the tradeoff being that they have few meaningful growth drivers

Superhero "Titan" Faces the Most Devious Foe of All... Cancer
Imagine for a moment you are the world's strongest protector -- TITAN, an invincible superhero who cannot be harmed by knife, bullet or bomb. Now, imagine Titan's mortal, regular-guy alter ego is told he has cancer and is dying. What then?

Short Squeeze & Speculation Could Push Onyx and Ligand Higher
By Brian Wilson, ContributorWhen I last covered Onyx Pharmaceuticals (NASDAQ:ONXX) on June 19th, the company was trading at a market capitalization of approximately $3 billion dollars ahead of a review of Kyprolis (carfilzomib) by the FDA's Oncologic Drugs Advisory Committee (ODAC)

Onyx Pharmaceuticals' Shorts Appear Focused on Upcoming Review
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) is a ~3 billion dollar pharmaceutical company which has improved its prospects dramatically in the last two years leading to a doubling of its stock price.Now trading at about $46/share on the heels of analyst upgrades (like Merrill Lynch's ""Buy"" rating on June 8th), it may be look a bit expensive

Unprecedented progression-free survival benefit with afatinib* associated with clinically meaningful improvements in life-limiting lung cancer symptoms and better quality of life
For NON-US media only

Folic acid may help reduce some childhood cancers
Folic acid fortification of foods may lower the incidence of the most common type of kidney cancer and a type of brain tumours in children.

Peter Andre 'hasn't stopped crying since bro's kidney cancer diagnosis'
Peter Andre, who has been keeping a vigil by his brother's side even since he was diagnosed with kidney cancer earlier this year, has revealed that he hasn't stopped crying since he found out his sibling had the disease.

Denise Richards designs sparking high heels for charity
Denise Richards is designing her very own pair of high heels for ShoeDazzle, the proceeds of which would go to charity.

Promising new drug targets against kidney cancer identified
Scientists have laid the foundation of completely understanding the intricacies of distinct kidney cancer subtypes, which could lead to better treatments for the disease.

Denise Richards designs shoes for charity
Denise Richards has designed a pair of pumps to raise money for a cancer charity.

Promising new drug targets against kidney cancer identified
Scientists have laid the foundation of completely understanding the intricacies of distinct kidney cancer subtypes, which could lead to better treatments for the disease.

Gene behind increased risk of deadly skin cancer identified
A novel gene mutation that appears to increase the risk of both inherited and sporadic cases of malignant melanoma, the most deadly form of skin cancer, has been identified in a major international study.

Mine-hunting software can revolutionize identifying human cancer cells
A new software developed for finding and recognizing undersea mines can help doctors identify and classify cancer-related cells.

Drug combo prolongs progression-free survival time in breast cancer
Combining two existing cancer drugs to treat post-menopausal women with advanced breast cancer resistant to hormonal therapy can significantly improve life expectancy without risk of the disease getting worse, a new study has suggested.

Targeting cancer cell metabolism can lead to more effective therapy
Scientists have long been looking for a therapy that can selectively target cancer cells, leaving other cells in our bodies unharmed but could not come up with some treatment, until now.

New compound kills cancer cells by starving them of glucose
Researchers at the Stanford University School of Medicine have identified a compound called STF-31 that attacks the Achilles' heel of certain cancer cells by depriving them of their energy source, the sugar glucose.

Agenus and NewVac Enter Into Agreement in the Area of Personalized Cancer Vaccines
Agenus Inc

LawyersandSettlements.com Honors National Diabetes Month by Reaching Out to Underserved Markets
LawyersandSettlements.com, the premier publication for Online Legal Media, today announced an educational campaign aimed at the Native American Indian population.

Long-term use of non-aspirin painkillers triples kidney cancer risk
People who take non-aspirin painkillers such as ibuprofen, diclofenac, and naproxen for more than 10 years are at a three-times higher chance of getting kidney cancer, according to new research.

Comment on this story

Share